Confirmatory adaptive group sequential designs for single-arm phase II studies with multiple time-to-event endpoints

被引:2
|
作者
Danzer, Moritz Fabian [1 ]
Terzer, Tobias [2 ]
Berthold, Frank [3 ]
Faldum, Andreas [1 ]
Schmidt, Rene [1 ]
机构
[1] Univ Munster, Inst Biostat & Clin Res, D-48149 Munster, Germany
[2] German Canc Res Ctr, Div Biostat, Heidelberg, Germany
[3] Univ Cologne, Ctr Integrated Oncol, Dept Pediat Oncol & Hematol, Cologne, Germany
关键词
martingale theory; multi-state models; sample size recalculation; survival analysis; INTERIM ANALYSES; CLINICAL-TRIALS; SURVIVAL-DATA; SAMPLE-SIZE; MODEL; SCHEDULE;
D O I
10.1002/bimj.202000205
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Existing methods concerning the assessment of long-term survival outcomes in one-armed trials are commonly restricted to one primary endpoint. Corresponding adaptive designs suffer from limitations regarding the use of information from other endpoints in interim design changes. Here we provide adaptive group sequential one-sample tests for testing hypotheses on the multivariate survival distribution derived from multi-state models, while making provision for data-dependent design modifications based on all involved time-to-event endpoints. We explicitly elaborate application of the methodology to one-sample tests for the joint distribution of (i) progression-free survival (PFS) and overall survival (OS) in the context of an illness-death model, and (ii) time to toxicity and time to progression while accounting for death as a competing event. Large sample distributions are derived using a counting process approach. Small sample properties are studied by simulation. An already established multi-state model for non-small cell lung cancer is used to illustrate the adaptive procedure.
引用
收藏
页码:312 / 342
页数:31
相关论文
共 50 条
  • [1] Bayesian single-arm phase II trial designs with time-to-event endpoints
    Wu, Jianrong
    Pan, Haitao
    Hsu, Chia-Wei
    [J]. PHARMACEUTICAL STATISTICS, 2021, 20 (06) : 1235 - 1248
  • [2] Mixed response and time-to-event endpoints for multistage single-arm phase II design
    Xin Lai
    Benny Chung-Ying Zee
    [J]. Trials, 16
  • [3] Mixed response and time-to-event endpoints for multistage single-arm phase II design
    Lai, Xin
    Zee, Benny Chung-Ying
    [J]. TRIALS, 2015, 16
  • [4] CONFIRMATORY ADAPTIVE DESIGNS FOR SURVIVAL TRIALS WITH SEVERAL TIME-TO-EVENT ENDPOINTS
    Schmidt, Rene
    [J]. NEURO-ONCOLOGY, 2022, 24 : 187 - 187
  • [5] Familywise error for multiple time-to-event endpoints in a group sequential design
    Thomsen, Henrik F.
    Lausvig, Nanna L.
    Pipper, Christian B.
    Andersen, Soren
    Damgaard, Lars H.
    Emerson, Scott S.
    Ravn, Henrik
    [J]. STATISTICS IN MEDICINE, 2024, 43 (18) : 3417 - 3431
  • [6] Bayesian enhancement two-stage design for single-arm phase II clinical trials with binary and time-to-event endpoints
    Shi, Haolun
    Yin, Guosheng
    [J]. BIOMETRICS, 2018, 74 (03) : 1055 - 1064
  • [7] Designing phase II studies in cancer with time-to-event endpoints
    Owzar, Kouros
    Jung, Sin-Ho
    [J]. CLINICAL TRIALS, 2008, 5 (03) : 209 - 221
  • [8] Adaptive Biomarker Population Selection in Phase III Confirmatory Trials with Time-to-Event Endpoints
    Li X.
    Chen C.
    Li W.
    [J]. Statistics in Biosciences, 2018, 10 (2) : 324 - 341
  • [9] Adaptive designs for single-arm phase II trials in oncology
    Englert, Stefan
    Kieser, Meinhard
    [J]. PHARMACEUTICAL STATISTICS, 2012, 11 (03) : 241 - 249
  • [10] Adaptive Designs for Two Candidate Primary Time-to-Event Endpoints
    Rauch, Geraldine
    Schuler, Svenja
    Wirths, Marius
    Englert, Stefan
    Kieser, Meinhard
    [J]. STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2016, 8 (02): : 207 - 216